Resumen de Adherencia a un protocolo de fondaparinux
L. Villamayor Blanco, Vanessa Jorge Vidal, Mª Carmen Mira Sirvent, S. Rabell Iñigo, Mónica Martínez Penella
Introduction: Fondaparinux is a new synthetic antithrombotic drug related to heparin that has shown a slight superiority of efficacy over enoxaparin in venous thromboembolism prophylaxis associated with hip and knee surgery, in contrast to enoxaparin. After a review of the evidence of fondaparinux and the protocol approval of its use by the Thromboembolism Committee, the Pharmacy Department created a prescription form to control the adherence to the fondaparinux protocol. Material and Methods: A retrospective study was developed by reviewing the clinical histories and the prescription forms of all patients that have received fondaparinux. Results: The clinical histories of 56 patients are reviewed: 37.50% hip prosthesis, 37.50% knee prosthesis, 17.86% hip fracture, 3.57% knee fracture, 3.57% in a off-label indication. The mean duration of the treatment was 4.8 days. Conclusions: This pharmaceutical intervention contribute to the rational use of fondaparinux
